Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Cite this article
Impact of Antiretroviral Medications on Fasting Lipid Parameters
1 Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy
2 Infectious Disease Clinic, Azienda USL 4 Prato, Italy
Rev. Cardiovasc. Med. 2014, 15(S1), 30–37;
Published: 20 January 2014
It is widely accepted that metabolic disease in human immunodeficiency virus (HIV) develops at the intersection of traditional risk factors and HIV-specific contributors, but in observational studies it is difficult to dissect the contribution of the two. This review describes the metabolic impact of antiretroviral medications recommended in the first-line treatment in HIV-infected naive patients. At a clinical level, coronary heart disease screening and management will continue to be of paramount importance in the long-term management of HIV-positive patients on antiretroviral therapy.
Coronary heart disease
Human immunodeficiency virus